文献速递消化道肿瘤与早癌消化内镜

HER2阳性胃癌空间图谱揭示靶向治疗耐药机制

Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy.
PubMed 文献 · Gut · 2026-03-06

该研究对30例胃癌(含15例HER2阳性)的1500余个感兴趣区域进行空间转录组分析,发现HER2阳性肿瘤微环境存在PD-L1表达;曲妥珠单抗耐药肿瘤中CLDN18.2表达升高,约三分之一患者出现EMT伴PD-L1和CCL2上调,另三分之一激活ERAD通路;T-DXd耐药肿瘤出现HLA缺失和氧化磷酸化通路增加。

要点

  • HER2阳性胃癌空间异质性显著,微环境中存在PD-L1表达。
  • 曲妥珠单抗耐药可表现为CLDN18.2升高、EMT或ERAD通路激活。
  • T-DXd耐药与HLA缺失及氧化磷酸化通路增加相关。

核心结论

  • HER2阳性胃癌对曲妥珠单抗和T-DXd存在多种获得性耐药机制,涉及CLDN18.2上调、EMT、ERAD通路激活、HLA缺失和氧化磷酸化增强。

研究设计与样本

  • 空间转录组分析(GeoMx Digital Spatial Profiler)应用于30例胃癌的1500余个感兴趣区域,其中15例HER2阳性胃癌后续接受曲妥珠单抗和T-DXd治疗。
  • 对获得性曲妥珠单抗或T-DXd耐药的患者配对样本进行分析,结果通过免疫组化、独立队列及患者来源异种移植和类器官验证。

主要发现

  • HER2阳性肿瘤在空间肿瘤微环境中呈现PD-L1表达。
  • 曲妥珠单抗耐药肿瘤中CLDN18.2表达升高。
  • 约三分之一HER2阳性胃癌患者曲妥珠单抗耐药时出现EMT,伴PD-L1和CCL2上调。
  • 另约三分之一曲妥珠单抗耐药患者激活ERAD通路,包括GOLM1等基因。
  • T-DXd耐药胃癌中观察到HLA缺失和氧化磷酸化通路增加。

临床怎么用

  • 耐药后应重新评估CLDN18.2、PD-L1、EMT及ERAD通路等标志物,为联合治疗试验提供依据。
  • 针对T-DXd耐药可考虑HLA缺失和氧化磷酸化通路作为潜在干预靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Human epidermal growth factor receptor 2 (HER2; ERBB2) is overexpressed or amplified in 15-20% of gastric cancers (HER2+ GC). Within individual HER2+ GCs, HER2/ERBB2 expression is often variable. Although HER2 therapeutic targeting improves outcomes for HER2+ GC patients, acquired resistance is frequent. OBJECTIVE: To spatially interrogate HER2+ GC interpatient and intrapatient heterogeneity and resistance mechanisms associated with HER2-targeting agents (trastuzumab, trastuzumab deruxtecan (T-DXd)). DESIGN: Spatial transcriptomic analysis (GeoMx Digital Spatial Profiler) was applied to >1500 regions of interest in 30 GCs-these contained 15 HER2+ GCs treated with trastuzumab and T-DXd subsequently. Analysis of patient-matched samples with acquired trastuzumab or T-DXd resistance revealed escape mechanisms. Results were validated by immunohistochemistry, independent cohorts and patient-derived xenografts and organoids. RESULTS: HER2+ tumours exhibited PD-L1 expression within the spatial tumour microenvironment. We observed increased expression of CLDN18.2, a promising therapeutic target, in trastuzumab-resistant tumours. One-third of HER2+ GC patients developed epithelial-mesenchymal transition (EMT) on trastuzumab resistance, associated with PD-L1 and CCL2 upregulation. Another third of trastuzumab-resistant HER2+ GC patients activated the endoplasmic reticulum-associated degradation (ERAD) pathway including genes such as GOLM1. HLA loss and increases in oxidative phosphorylation pathways were observed in T-DXd-resistant GCs. CONCLUSION: Our results delineate multiple acquired resistance mechanisms to trastuzumab and T-DXd in HER2+ GC in vivo. This information may guide trials combining trastuzumab or T-DXd with new agents to enhance the efficacy and durability of HER2 blockade.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Sheng T, Sundar R, Srivastava S, et al. Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy. Gut. 2026. PMID: 41167802. doi:10.1136/gutjnl-2024-334667

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。